New immune pathways from chronic post-viral lung disease.

Area of Science:

• Immunology
• Pulmonology
• Infectious Disease

Background:

• Chronic inflammatory lung diseases, including chronic obstructive lung disease (COPD), significantly impact public health.
• Understanding the underlying immunopathogenesis is crucial for developing effective treatments.
• Existing models often fail to fully recapitulate the complexity of chronic lung inflammation post-infection.

Purpose of the Study:

• To establish and characterize a mouse model of chronic inflammatory lung disease following respiratory viral infection.
• To elucidate the distinct immunological phases and cellular mechanisms driving disease progression.
• To identify potential diagnostic and therapeutic targets for human COPD.

Main Methods:

• Establishment of a mouse model mimicking human COPD after viral infection.
• Characterization of early (3 weeks) and late (7 weeks) disease phases.
• Analysis of immune cell populations (dendritic cells, CD4+ T cells, iNKT cells, macrophages) and molecular interactions (interferon, IgE receptor, T-cell receptor, CD1d, IL-13).

Main Results:

• The early phase involves type I interferon-driven activation of the high-affinity IgE receptor (FcepsilonRI) on dendritic cells, recruiting IL-13-producing CD4+ T cells.
• The late phase is mediated by invariant natural killer T (iNKT) cells and macrophages through CD1d-TCR interactions, leading to IL-13 overproduction.
• This innate immune axis, characterized by iNKT cells and alternatively activated macrophages (chitinase 1+), is also observed in human COPD patients.

Conclusions:

• Two distinct immune pathways drive early and late phases of chronic inflammatory lung disease in this model.
• The identified innate immune axis involving iNKT cells and macrophages is relevant to human COPD.
• These findings offer novel targets for the diagnosis and therapy of chronic inflammatory lung diseases.